Overview: Vasoactive Intestinal Polypeptide TestIntroduction: The Vasoactive Intestinal Polypeptide Test measures VIP to diagnose neuroendocrine tumors, causing diarrhea or flushing. Aligned with 2023 NANETS guidelines, it uses biochemical methods for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected neuroendocrine tumors.
Other Names: VIP Assay, Vasoactive Intestinal Peptide Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: VIP testing began in the 1970s with neuroendocrine research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures VIP to diagnose neuroendocrine tumors, guides treatment, and evaluates patients with diarrhea or flushing.
Test Parameters: 1. VIP Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of diarrhea, flushing, or neuroendocrine symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document diarrhea, flushing, or history of neuroendocrine tumors. Include current medications, especially somatostatin analogs.
Consent: Written consent required, detailing the tests purpose, neuroendocrine tumor implications, and risks of sample collection.
Procedural Considerations: Uses radioimmunoassay or ELISA to measure VIP levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for neuroendocrine tumor diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Medications like octreotide may alter VIP levels.
Clinical Significance: Elevated VIP confirms neuroendocrine tumors like VIPoma, guiding surgical or medical therapy. Normal levels may require imaging or other tumor markers.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Chromogranin A, CT/MRI, or octreotide scan to confirm neuroendocrine tumor diagnosis.
Test Limitations: Non-specific for tumor type; clinical correlation is needed. Sample quality affects sensitivity.
References: NANETS Neuroendocrine Guidelines, 2023; Journal of Clinical Oncology, Yao JC, 2022.
